8-K: Verano Holdings Reports Q1 2026 Results, Authorizes $20M Share Buyback

Verano Holdings Corp. announced its first quarter 2026 financial results, reporting $208 million in revenue and authorizing a $20 million share repurchase program.

Summary

• Verano Holdings Corp. reported first quarter 2026 revenue of $208 million, a slight 1% increase from the prior quarter and a 1% decrease year-over-year.
• Gross profit for the quarter was $99 million, representing a 48% gross profit margin.
• Selling, General & Administrative (SG&A) expenses were $86 million, or 41% of revenue.
• The company reported a net loss of $18 million for the quarter.
• Adjusted EBITDA was $49 million, or 24% of revenue.
• Net cash provided by operating activities was $19 million.
• Capital expenditures for the quarter were $15 million.
• The Board of Directors authorized a share repurchase program of up to $20 million over the next 12 months.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, with stable revenue and positive operational cash flow offset by a net loss and slight year-over-year revenue decline. The share repurchase authorization and positive commentary on industry catalysts provide upside potential.

Positives

• Revenue increased by 1% sequentially to $208 million, marking the second consecutive quarter of revenue growth.
• Achieved Adjusted EBITDA of $49 million, representing a 24% margin.
• Generated $19 million in net cash from operating activities.
• Strengthened retail footprint in Florida with new store openings.
• Secured a new $195 million credit facility to fund growth initiatives.
• Announced a $20 million share repurchase authorization, indicating confidence in future performance and a commitment to shareholder value.
• The company's operations span 13 states with 162 dispensaries and 14 production facilities.

Negatives

• Revenue decreased by 1% year-over-year.
• Reported a net loss of $18 million for the quarter.
• Gross profit margin decreased to 48% from 51% in the prior quarter, primarily due to increased promotional activity.
• SG&A expenses increased slightly year-over-year as a percentage of revenue (41% vs. 40%) due to new store openings.
• The net loss increased compared to the prior year, largely due to expenses associated with repaying the prior 2022 credit agreement.

Risks

• Increased competition and promotional activity in wholesale markets impacted year-over-year revenue.
• Expenses associated with repaying prior credit agreements contributed to the net loss.
• The company is subject to limitations on share repurchases, including daily trading volume caps and other regulatory requirements.
• Forward-looking statements are subject to inherent uncertainties and risks, including those described in the company's annual report.

Future Outlook

The company reiterates its 2026 capital expenditures guidance range of $30 million to $50 million. Management views 2026 as a potentially transformative year, especially with the potential Schedule III designation for medical cannabis, which is expected to unlock significant medical, research, and commercial potential.

Management Comments

• "Following last weeks historic rescheduling announcement and a strong first quarter highlighted by sequential revenue growth, 2026 has the potential to be a transformative year for Verano and the entire industry."
• "Throughout the first quarter, we secured our new $195 million credit facility to fund strategic growth initiatives, strengthened our retail footprint in Florida, elevated our cultivation and processing operations, and launched new products that continue to generate market share growth in the fastest-growing categories."
• "As we aim to drive further momentum for the business in 2026, Verano is well-positioned to quickly capitalize on a final Schedule III designation - a game-changing catalyst delivered by President Trump and Acting Attorney General Blanche that promises to unlock the full medical, research and commercial potential of America's next great industry while providing meaningful health and wellness benefits to millions of Americans nationwide."
• "Given business performance and the transformative Schedule III medical cannabis designation, we believe the share repurchase authorization provides Verano further optionality to deploy capital in pursuit of growth initiatives."
• "The share repurchase authorization offers Verano another strategic outlet to unlock value for the Company and our shareholders, including strengthening the balance sheet and accretive M&A opportunities."

Industry Context

StockSavvy.ai notes that Verano's Q1 2026 results and forward-looking commentary are closely tied to the evolving regulatory landscape of the cannabis industry, particularly the anticipated Schedule III rescheduling in the U.S. This potential reclassification could significantly impact market dynamics, research, and commercialization opportunities for cannabis companies.

Comparison to Industry Standards

• The company's gross profit margin of 48% is within its guidance range, but slightly down from 51% in Q4 2025, indicating potential pressure from promotional activities common in the competitive cannabis market.
• Adjusted EBITDA margin of 24% is a key performance indicator in the cannabis sector, and Verano's figure is within its historical range, suggesting operational efficiency despite market challenges.
• The $208 million in revenue for Q1 2026 places Verano among the larger multi-state operators in the U.S. cannabis market, competing with companies like Curaleaf, Green Thumb Industries, and Trulieve, which also report significant quarterly revenues.

Stakeholder Impact

• Shareholders: The $20 million share repurchase authorization may lead to increased shareholder value through reduced outstanding shares and potential stock price appreciation.
• Employees: Continued investment in operations and potential growth initiatives could lead to job stability or creation.
• Creditors: The company's ability to generate operating cash flow and secure new credit facilities supports its ability to service debt.
• Suppliers: Ongoing operations and expansion in cultivation and retail suggest continued demand for goods and services.

Next Steps

• Continue to strengthen retail footprint in Florida.
• Elevate cultivation and processing operations.
• Launch new products to drive market share growth.
• Capitalize on potential Schedule III designation for medical cannabis.
• Execute share repurchases under the $20 million authorization over the next 12 months.
• Monitor and manage operations across 13 states.

Key Dates

Recommendation

The filing shows stable sequential revenue growth and positive operating cash flow, alongside a significant share repurchase authorization, which are positive indicators. However, the continued net loss and slight year-over-year revenue decline, coupled with the inherent volatility of the cannabis industry and regulatory uncertainties, warrant a cautious 'hold' recommendation until further clarity on industry-wide catalysts and sustained profitability emerges.

Keywords

Verano Holdings, Cannabis, Financial Results, Q1 2026, Revenue, Adjusted EBITDA, Share Repurchase, SEC Filing